Indivior (INDV) announced that the FDA has approved label changes for Sublocade including a rapid initiation protocol and alternative injection sites, marking a significant advancement in the treatment of moderate to severe opioid use disorder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INDV:
- Indivior’s SUBLOCADE® Receives FDA Approval for Rapid OUD Treatment Protocol
- Indivior’s Earnings Call: Growth Amidst Challenges
- Indivior price target lowered to $15 from $16 at Craig-Hallum
- Indivior price target lowered to 1,100 GBp from 1,400 GBp at Stifel
- Indivior reports Q4 adjusted EPS 32c, consensus 26c